Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Physiomics PLC (GB:PYC)
LSE:PYC
Holding GB:PYC?
Track your performance easily
PYC Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range0.60p - 2.10p
Previous Close0.8p
Volume8.17M
Average Volume (3M)1.70M
Market Cap
£1.63M
Enterprise Value1.21M
Total Cash (Recent Filing)£416.59K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Mar 11, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding203,210,000
10 Day Avg. Volume4,164,726
30 Day Avg. Volume1,695,824
Standard Deviation0.35
R-Squared0.06
Alpha0.00928
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)2.53
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Physiomics News
PremiumCompany Announcements
Physiomics Strengthens Collaboration with Numab Therapeutics
PremiumCompany Announcements
Physiomics Lands Major Contract in Cancer Drug Development
PremiumCompany Announcements
Physiomics Gains Strong Shareholder Support at AGM
PremiumCompany Announcements
Physiomics CEO Boosts Shareholding, Signals Confidence
PremiumCompany Announcements
Physiomics CEO Increases Stake in CompanyPremiumCompany Announcements
Physiomics Strengthens Leadership with New Senior Appointment
PremiumCompany Announcements
Physiomics PLC Announces 2024 Annual General MeetingPremiumCompany Announcements
Physiomics Wins New Contract with Cancer Research UKOptions Prices
Currently, No data available
---
Ownership Overview
PYC FAQ
What was Physiomics PLC’s price range in the past 12 months?
Physiomics PLC lowest share price was 0.60p and its highest was 2.10p in the past 12 months.
What is Physiomics PLC’s market cap?
Currently, no data Available
When is Physiomics PLC’s upcoming earnings report date?
Physiomics PLC’s upcoming earnings report date is Mar 11, 2025 which is in 79 days.
How were Physiomics PLC’s earnings last quarter?
Physiomics PLC released its earnings results on Sep 27, 2024. The company reported -0.003p earnings per share for the quarter, missing the consensus estimate of N/A by -0.003p.
Is Physiomics PLC overvalued?
According to Wall Street analysts Physiomics PLC’s price is currently Overvalued.
Does Physiomics PLC pay dividends?
Physiomics PLC does not currently pay dividends.
What is Physiomics PLC’s EPS estimate?
Physiomics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Physiomics PLC have?
Physiomics PLC has 203,208,720 shares outstanding.
What happened to Physiomics PLC’s price movement after its last earnings report?
Physiomics PLC reported an EPS of -0.003p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.839%.
Which hedge fund is a major shareholder of Physiomics PLC?
Currently, no hedge funds are holding shares in GB:PYC
---
Physiomics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.51%
12-Months-Change
Fundamentals
Return on Equity
-149.67%
Trailing 12-Months
Asset Growth
-37.34%
Trailing 12-Months
Company Description
Physiomics PLC
Physiomics PLC a United Kingdom-based firm providing services to pharmaceutical companies through outsourced systems and computational biology. The company is mainly engaged in the development of models to streamline the drug discovery and development process. It focuses on the development of Virtual Tumour Clinical used to predict optimal treatment for human clinical trials; Cardiac tox prediction service used to predict unwanted toxic side effects of drug candidates, and drug combinations database, for researchers and clinicians to access literature data on pre-clinical and clinical treatments and their effects.
---
Technical Analysis
---